NorthStar Medical Radioisotopes has dosed its first patient in a clinical trial using its electron accelerator-produced Cu-67. The trial is being conducted by Clarity Pharmaceuticals to test the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma. This milestone marks an important step in the exclusive supply agreement between NorthStar and Clarity. NorthStar is the first commercial-scale supplier of Cu-67, a therapeutic radioisotope, while Clarity leads in copper-based theranostics. NorthStar's production process uses an efficient electron accelerator technology, and the Cu-67 is suitable for Clarity's products using their proprietary SAR Technology platform, preventing leakage of copper isotopes into the body.
Mon, 28 Aug 2023 13:18:47 GMT | BioSpace